Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Audio-Described Menopause Education Program in Visually Impaired Women

17 augusti 2026 uppdaterad av: İlknur Münevver Gönenç, Ankara University

The Effect of Education Provided Through Audio Description Method on Menopause Knowledge and Menopausal Symptoms in Visually Impaired Women: Randomized Controlled Trial

This randomized controlled trial was conducted to evaluate the effect of an audio-described menopause education program on menopause knowledge and menopausal symptoms in women with visual impairment. A total of 46 women who were members of the Ankara Branch of the Altı Nokta Blind Association were randomly assigned to either an intervention group (n=23) or a control group (n=23). The intervention group received an accessible menopause education program, while the control group did not receive the intervention during the study period. Outcomes included menopause knowledge and menopausal symptom severity, assessed using standardized measurement tools.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This study was designed as a randomized controlled trial in accordance with CONSORT guidelines. It aimed to determine the effectiveness of an audio-described menopause symptom and awareness education program for women with visual impairment on menopause knowledge and menopausal symptoms.

The study sample consisted of 46 women who were members of the Ankara Branch of the Altı Nokta Blind Association. Participants were randomly allocated in a 1:1 ratio to either the intervention group (n=23) or the control group (n=23).

Data were collected using a demographic information form, the Menopause Knowledge Scale, and the Menopause Rating Scale. The intervention group received an audio-described educational program designed to improve accessibility for women with visual impairment, while the control group did not receive the intervention during the study period.

Statistical analyses included descriptive statistics, Fisher-Freeman-Halton Exact test, Pearson chi-square test, Cronbach's alpha reliability analysis, assessment of skewness and kurtosis for normality, Pearson correlation analysis, independent samples t-test, and analysis of covariance (ANCOVA). Statistical significance was set at p < 0.05.

Studietyp

Interventionell

Inskrivning (Faktisk)

46

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Turkiet (Türkiye)
    • Altindağ
      • Ankara, Altindağ, Turkiet (Türkiye), 06250
        • Ankara University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Being a member of the Ankara Branch of the Altı Nokta Blind Association,
  • Being a woman with visual impairment (congenital or acquired),
  • Being female,
  • Being between 40 and 60 years of age,
  • Being able to speak Turkish,
  • Having no additional communication problems other than visual impairment,
  • Having experienced at least 12 months of amenorrhea (STRAW+1 criteria).

Exclusion Criteria:

  • Refusal to participate in the study,
  • Previous participation in a structured menopause-related education program,
  • Use of pharmacological treatment for the management of menopausal symptoms,
  • Use of non-pharmacological methods for menopausal symptom management (e.g., yoga, aromatherapy, phytotherapy, etc.),
  • Surgical menopause,
  • Having additional disabilities other than visual impairment (hearing, intellectual, or physical disabilities).

Withdrawal / Discontinuation Criteria

  • Initiation of any pharmacological or non-pharmacological intervention aimed at reducing menopausal symptoms during the study period,
  • Non-adherence to the study protocol,
  • Voluntary withdrawal from the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Audio description-based menopause education program
Participants in this arm received an audio-described menopause education program designed for women with visual impairment. The intervention aimed to improve menopause knowledge and reduce menopausal symptom-related difficulties. The educational content was delivered in an accessible format tailored to participants' needs. Outcomes were assessed using standardized measurement tools.
Beteende: Audio-Described Menopause Education Program
This intervention consisted of a structured audio-described menopause education program developed for women with visual impairment. The program provided accessible information about menopause, menopausal symptoms, and symptom management strategies to improve knowledge and awareness.
Inget ingripande: Standard of care
Participants in this arm did not receive the audio-described menopause education program during the study period. They continued with their usual daily life without any structured educational intervention related to menopause. Outcomes were assessed at the same time points using standardized measurement tools.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Menopause Knowledge
Tidsram: Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
To assess changes in menopause knowledge following the audio-described menopause education program. The total score of the "Menopause Knowledge Scale" ranges from 14 to 70, with higher scores indicating a higher level of overall knowledge about menopause. Similarly, higher scores on the General Menopause Knowledge subscale (5-25) and the Knowledge of Menopausal Symptoms and Management subscale (9-45) indicate greater knowledge in the respective domains.
Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
Menopausal Symptom Severity
Tidsram: Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
To evaluate changes in menopausal symptom severity following the audio-described menopause education program. The Menopause Rating Scale was used to assess the severity of menopausal symptoms.The total score of the scale ranges from 0 to 44. Higher total scores indicate greater severity of menopausal symptoms and a more negative impact on quality of life.
Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Ankara University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 februari 2025

Primärt slutförande (Faktisk)

15 juli 2025

Avslutad studie (Faktisk)

15 juli 2025

Studieregistreringsdatum

Först inskickad

3 juli 2026

Först inskickad som uppfyllde QC-kriterierna

17 augusti 2026

Första postat (Faktisk)

19 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • Ankara University Thesis

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

De-identified participant data, including baseline characteristics and outcome measures, will be shared. No identifiable personal data will be included.

Tidsram för IPD-delning

De-identified individual participant data will be available beginning 6 months after publication of the study results and will remain available for 5 years.

Kriterier för IPD Sharing Access

Access to individual participant data and supporting documents will be granted to qualified researchers who submit a methodologically sound research proposal. Requests must be approved by the principal investigator or study sponsor. Data will be provided for non-commercial academic research purposes only. All data will be de-identified, and no personally identifiable information will be shared. Data will be shared via secure electronic transfer upon approval.

IPD-delning som stöder informationstyp

  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera